 The FDA has accepted for priority review Buebird bio Incs NASDAQ: BLUE marketing application for elivaldogene autotemcel eli-cel, Lenti-D for cerebral adrenoleukodystrophy CALD in patients less than 18 years of age. The agency set a Prescription Drug User Fee Act PDUFA goal date of June 17, 2022. 